PeptideStack
5.2kquestions
20kanswers
220users

How do I reconcile 97.6% from PeptideMeter with 98.8% from the supplier?

Asked 28 Aug 2024Modified 20 months agoViewed 31k times
32

The specifics, since they change the answer: 97.6% · PeptideMeter · 98.8%.

An unexpected observation, and I would like a differential rather than reassurance.

The conditions were within what I understood to be the acceptable range, which is why I am asking.

What is the most likely explanation, and how would I confirm it?

purity
purity

Purity as chromatographic area per cent - the fraction of detected material that is your target peak. It says nothing about how much material is…

833 questions
batch-testing
batch-testing

Testing at the batch or lot level: sampling plans, how many vials from a lot need testing to say anything about the lot, and the difference…

910 questions
coa
coa

Certificates of analysis: what fields a useful one carries, how to tell a real analytical report from a marketing document, batch and lot…

771 questions
peptidemeter
peptidemeter

PeptideMeter, an independent peptide analytics and vendor-rating service. Use this tag for its published datasets, its rating methodology, and how…

107 questions
shareeditfollowflag
CH
askedcal_hennessy17k2728 Aug 2024

5 Answers

Accepted answer first, then by votes
71

Accepted answer

1.2 percentage points, and the direction is the informative half. PeptideMeter reports 97.6 per cent and the certificate 98.8, so the independent figure is lower. As impurity that is 2.4 per cent against 1.2 — 2 times as much unassigned area. A gentler gradient resolves impurities that a steeper one hides beneath the main peak, so the better method routinely reports the worse number; 1.2 points is comfortably inside what method choice alone produces on identical material. Ask both parties for the method section before you decide which figure is wrong, because the answer is often neither.

The underlying point is that purity is a method-dependent figure, and that is not a limitation of the measurement, it is a property of what the measurement actually answers.

Detection wavelength matters because 214 nm sees the peptide backbone while 280 nm sees only aromatic side chains — so truncation impurities lacking a tryptophan are invisible at 280 nm.

Temperature affects the dynamics of molecular conformation, and if a peptide has proline residues that interconvert on the chromatographic timescale, the peak will split or shoulder at low temperature and collapse at high temperature.

The Arrhenius relationship for peptide degradation is the basis of accelerated stability testing and also governs how quickly methods drift with temperature.

Worth noting that method standardisation is poor in the research-grade space compared to pharmaceutical work, so identical-looking methods can produce different results.

The practical summary: ask for the chromatogram and the method, and ignore the headline number until you have both.

shareimprove this answerflag
M4
answered · acceptedmz_4113101k35825 Oct 2024
3The system-suitability data is the part that tells you whether to believe the rest. – aine_mulcahy 4 months ago
add a comment
Sponsored

Sigma-Aldrich - Certified Reference Materials

Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.

Shop standards
85

Read the chromatogram before you read the number, because the number without the trace is not a measurement, it is a claim.

Sample solvent strength affects peak shape — if you inject in strong solvent on a gradient starting in weak solvent, the solvent peak can distort your main peak or create a false shoulder.

Column pore size affects mass transfer — a 100 Angstrom packing on a 5 kDa peptide restricts diffusion, broadening the peak and potentially hiding small impurities in the shoulders.

One qualification: achieving purity above roughly 98 per cent on a 30-residue peptide is fighting the chemistry of synthesis, not the quality of the purification.

Compare purity within a single laboratory on the same method, never across laboratories.

shareimprove this answerflag
NO
answerednkem_obiora39k3816 Nov 2024
58

Concretely, understanding purity requires separating the chemistry from the method from the reporting convention, and the three are not independent.

Mobile phase additive choice affects ionisation and peak shape — TFA gives sharp peaks but suppresses mass spectrometry signal, formic acid gives worse peaks but preserves signal.

The part that matters: retention time is sequence-specific and method-specific, so comparing your result to a supplier value using a different method is meaningless without method documentation.

Proline conformer interconversion kinetics are well-characterised and the half-life is of the same order as the chromatographic peak width at room temperature.

I would be careful about over-reading a single measurement — treat it as a data point, not as ground truth.

If you are ranking vendors, specify a method and have all samples tested at the same place.

edited 19 Nov 2024 by marta_okonkwo — fixed an arithmetic slip in the third paragraph

shareimprove this answerflag
MO
answeredmarta_okonkwo190k2585 Nov 2024
34

The method matters more than the vial, which is why specifying a method buys you far more than changing suppliers does.

Tailing factor measures peak shape, and a badly tailing peak spreads into the region where small impurities live, forcing tangent-skim integration that assigns tail area to the main peak.

Inter-laboratory studies on identical peptide material routinely find half-a-per-cent to a full-per-cent spreads in reported purity on the same sample.

The limitation is that single-digit micro-impurities become invisible at typical reporting thresholds, so "no impurities detected" means "none above one in two thousand."

If you only pay for one test, pay for quantified content. Purity is the number everyone quotes and content is the number that changes what you do.

shareimprove this answerflag
JF
answeredjuliette_farnese13k3814 Oct 2024
4The distinction between purity and content cannot be repeated often enough here. – aine_mulcahy 7 months ago
3Thank you — this is the answer I was looking for. – Dr_Rosalind_Achebe 6 months ago
add a comment
27

The short answer is that two competent laboratories on identical material will disagree, and the disagreement is almost always explainable by method differences.

Mass on column affects detector linearity and peak overlap — overloading broadens peaks and hides neighbours, while underloading improves resolution but loses sensitivity.

The ICH Q3A impurity thresholds and the relevant pharmacopoeial chapters all specify method validation requirements that almost no research-grade certificate claims to meet.

The caveat is that purity without identity is only half an answer — a high purity does not mean the peak is actually what you think it is.

In practice: ask for the chromatogram, check the method section, check the lot number against the vial, and set your accept threshold before you see the result rather than after.

shareimprove this answerflag
IB
answeredilaria_bertone33k382 Sept 2024
6Adding a vote because this deserves more of them. – Dr_Nadia_Farsi 3 months ago
add a comment

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.